TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04504045
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
Study: NCT02647359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study: NCT02736539
Drug: CBS 2004 (galacto-oligosaccharides)
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBS 2004 active treatment
Study: NCT02736539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT03310541
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
Study: NCT03050476
Drug: RESCAP®
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Study: NCT03050476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous application before, during, and for 24 or 96 hours after heart surgery
Study: NCT00490425
Drug: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04574544
Drug: Zinc Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
Study: NCT00093145
Drug: Herceptin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT00723177
Drug: Placebo (PCB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
Study: NCT00001481
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study: NCT00748436
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (placebo tablet + placebo tablet) BID per os 12 weeks
Study: NCT04287920
Drug: Acomprosate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
Study: NCT01069783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator once daily for the duration of the trial
Study: NCT01435577
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum 12 administrations over 48 hours
Study: NCT00680316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
Study: NCT01876121
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT03328897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo
Study: NCT00812292
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05413187
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil and Chlorophyl
Study: NCT03189914
Drug: RX-3117
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX-3117 will be administered orally in combination with Abraxane.
Study: NCT00512759
Drug: Goal-directed preload and afterload decrement
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
Study: NCT01343719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for administration
Study: NCT00270491
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01097135
Drug: Duraprep Surgical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005854
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005854
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00447213
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals,12 weeks
Study: NCT02016924
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered once daily according to dosing recommendations per product monograph
Study: NCT02016924
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution administered orally
Study: NCT02016924
Drug: Third Unboosted Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
Study: NCT02016924
Drug: F/TAF TOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral suspension
Study: NCT04339777
Drug: Cyclophosphamide (Cytoxan)
Normalized name: cyclophosphamide Oral Tablet [Cytoxan]
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
Study: NCT03888144
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of ketorolac taken by mouth every 6 hours for 5 days
Study: NCT00967850
Drug: Intravitreal Injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1,25 mg in 0,05 ml
Study: NCT00967850
Drug: Photodynamic Therapy (Visudyne)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy on day 1 as described in standard clinical guidelines.
Study: NCT01863680
Drug: Gonadotropin-releasing hormone (GnRH) analogue
Normalized name: Gonadotropin releasing hormone analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
Study: NCT04489446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
Study: NCT01448746
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg 12 hours before surgery and 12 hours later surgery
Study: NCT02244944
Drug: EZ-Urso combination therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
Study: NCT04830449
Drug: HCP1904-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04830449
Drug: RLD2001-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT03821376
Drug: Contrast enhanced ultrasound with Lumason
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
Study: NCT03581071
Drug: TS-143
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00519480
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
Study: NCT00519480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as an oral tablets.
Study: NCT00137332
Drug: GAP-486 (ZP-123)
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01144312
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
Study: NCT03689010
Drug: Finacea® (Azelaic acid Foam) 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelaic acid foam 15%
Study: NCT03689010
Drug: Vehicle of the test product
Normalized name: The Magic Bullet Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of the test product
Study: NCT02621606
Drug: [11C]MK-6884
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus dose of \~370 MBq \[11C\]MK-6884
Study: NCT02044510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules to the intervention arm
Study: NCT01813799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
Study: NCT00875394
Drug: Comparator: Antidiabetic Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient can take any oral antidiabetic drug (other than metformin)
Study: NCT03455075
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
Study: NCT00290940
Drug: CS-917
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01229345
Drug: Breakfast & exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
Study: NCT04409964
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Study: NCT01259713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
Study: NCT01732393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004010
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004010
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004010
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003457
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT02199847
Drug: Pharmaton® Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01492881
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, 30mg/m2, Day 4
Study: NCT02566395
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
Study: NCT02246998
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet administered orally once daily with food
Study: NCT02246998
Drug: ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/300 mg FDC tablet administered orally once daily with food
Study: NCT01601808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once a day, continuously throughout the study
Study: NCT03030066
Drug: DS-1001b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic not assigned
Study: NCT03070730
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: t.i.d
Study: NCT02052349
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of ABT-333
Study: NCT00004179
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004179
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004179
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01982916
Drug: AGR tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982916
Drug: Placebo (for AGR tablet and/or Active Comparator)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00044044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to Lurasdione and Haloperidol
Study: NCT02257697
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02943135
Drug: placebo in-situ gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in-situ gel
Study: NCT01152619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeated dose
Study: NCT03871387
Drug: Deep Group
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Study: NCT03871387
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2
Study: NCT02417246
Drug: Generic A
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication will be taken for 7 days
Study: NCT02417246
Drug: Generic B
Normalized name: Generic B-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication will be taken for 7 days
Study: NCT04603989
Drug: HNC042 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
Study: NCT04603989
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo , Intravenous route , multiple ascending doses
Study: NCT01001494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice-daily by inhalation for 24 weeks
Study: NCT00406029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID capsules
Study: NCT00406029
Drug: Other Parkinson's Disease treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
Study: NCT01152619
Drug: RO4989991
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeated dose
Study: NCT03283137
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
Study: NCT03078101
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT00351884
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03761264
Drug: Odontopaste®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
Study: NCT05574543
Drug: AGA111
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study: NCT05574543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
Study: NCT00703807
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
Study: NCT00782080
Drug: Sedariston
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John´s Wort (100 mg) Valerian Extract (50 mg)
Study: NCT00782080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03336840
Drug: ProMetS probiotics powder
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study: NCT04323189
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered daily for 7 days, with a study day on day 7.
Study: NCT02182037
Drug: BIBT 1011 BS placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01955460
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04106830
Drug: Intravenous steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
Study: NCT02955186
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once per day for 8 days
Study: NCT01746602
Drug: Timoptic® 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timoptic® 0.5% Eye Drops, Merck, single instillation
Study: NCT01746602
Drug: Timophtal sine® 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
Study: NCT02658162
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
Study: NCT01899144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study: NCT02213757
Drug: Premarin vaginal estrogen cream
Normalized name: estrogens, conjugated (USP) Vaginal Cream [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02213757
Drug: Placebo vaginal cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vaginal cream manufactured to mimic Premarin vaginal cream
Study: NCT00803244
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
Study: NCT00803244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
Study: NCT00751881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet~Oral administration
Study: NCT00745264
Drug: Diractin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ketoprofen to 4 joints
Study: NCT00745264
Drug: Diractin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 and 400 mg Ketoprofen used concomittant with heat
Study: NCT00745264
Drug: Diractin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 and 400 mg Ketoprofen concomittant with moderate exercise
Study: NCT03049540
Drug: Placebo 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
Study: NCT01347684
Drug: Standard care using current drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Drug therapy
Study: NCT04495712
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aldosterone blocker
Study: NCT04495712
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical in appearance to spironolactone study drug
Study: NCT01129310
Drug: Irinotecan-Capecitabine-Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1